Mihealsick E, Word A, Scully EP. The impact of sex on HIV immunopathogenesis and therapeutic interventions. J Clin Invest. 2024;134:e180075.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Virological Failure [Internet]. EACS Guidelines. [cited 2024 Jan 24]. Available from: https://eacs.sanfordguide.com/art/eacs-virological-failure.

Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach [Internet]. Geneva: World Health Organization; 2021 [cited 2024 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK572729/.

Management of people with HIV and antiretroviral therapy experience [Internet]. Guidelines for the use of antiretroviral angents in adults and adolescents with HIV. 2024 [cited 2024 Nov 21]. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/virologic-failure.

Low-level HIV viremia: definitions, predictors, mechanisms, and clinical outcomes. The Ontario HIV Treatment Network [Internet]. 2024 [cited 2024 May 1]. Available from: https://www.ohtn.on.ca/rapid-response-low-level-hiv-viremia-definitions-predictors-mechanisms-and-clinical-outcomes/.

Esteban-Cantos A, Montejano R, Pinto-Martínez A, Rodríguez-Centeno J, Pulido F, Arribas JR. Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians. The Lancet HIV. 2024;11:e333–40.

Article  CAS  PubMed  Google Scholar 

Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother. 2014;58:3585–98.

Article  PubMed  PubMed Central  Google Scholar 

Calcagno A, Motta I, Ghisetti V, Lo Re S, Allice T, Marinaro L, et al. HIV-1 very Low level viremia is associated with virological failure in highly active antiretroviral treatment-treated patients. AIDS Res Hum Retrovir. 2015;31:999–1008.

Article  CAS  PubMed  Google Scholar 

Helou E, Shenoi S, Kyriakides T, Landry M-L, Kozal M, Barakat LA. Characterizing patients with very-low-level HIV viremia: a community-based study. J Int Assoc Provid AIDS Care. 2017;16:261–6.

Article  PubMed  Google Scholar 

Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr. 2012;60:473–82.

Article  PubMed  Google Scholar 

Chen G-J, Sun H-Y, Chang S-Y, Cheng A, Huang Y-S, Huang S-H, et al. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy. Int J Infect Dis. 2021;105:147–51.

Article  CAS  PubMed  Google Scholar 

Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, Miller V, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16:1967–9.

Article  PubMed  Google Scholar 

Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther. 2008;13:927–36.

Article  CAS  PubMed  Google Scholar 

Garcia-Gasco P, Maida I, Blanco F, Barreiro P, Martin-Carbonero L, Vispo E, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother. 2008;61:699–704.

Article  CAS  PubMed  Google Scholar 

Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, Klein M, et al. Magnitude of Virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205:1230–8.

Article  PubMed  PubMed Central  Google Scholar 

Crespo-Bermejo C, de Arellano ER, Lara-Aguilar V, Valle-Millares D, Gómez-Lus ML, Madrid R, et al. Persistent low-level viremia in persons living with HIV undertreatment: An unresolved status. Virulence. 2021;12:2919–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel A, Patel K, Pujari S, Patel J, Kumar A. Virological outcome and frequency of low-level viremia in patients receiving generic dolutegravir-containing regimen at a large tertiary care clinic in Western India. Indian J Sex Transm Dis. 2021;42:31.

Article  Google Scholar 

Underwood M, Urbaityte R, Wang R, Horton J, Oyee J, Wynne B, et al. Dolutegravir + lamivudine vs. Dolutegravir + Tenofovir Disoproxil fumarate/Emtricitabine: very-low-level HIV-1 replication through 144 weeks in the GEMINI-1 and GEMINI-2 studies. Viruses. 2024;16:405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elén S, Björkman P, Zazzi M, Böhm M, Bernal E, Sönnerborg A, et al. Low-level HIV viraemia during antiretroviral therapy: longitudinal patterns and predictors of viral suppression. HIV Medicine. 2024;25:107–16.

Article  PubMed  Google Scholar 

Jacobs JL, Halvas EK, Tosiano MA, Mellors JW. Persistent HIV-1 viremia on antiretroviral therapy: measurement and mechanisms. Front Microbiol. 2019;10:2383.

Article  PubMed  PubMed Central  Google Scholar 

Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, et al. Viral and host mediators of non-suppressible HIV-1 viremia. Nat Med. 2023;29:3212–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun X, Zhang H, Kong X, Li N, Zhang T, An M, et al. Low-level viremia episodes appear to affect the provirus composition of the circulating cellular HIV reservoir during antiretroviral therapy. Front Microbiol. 2024;15:1376144.

Article  PubMed  PubMed Central  Google Scholar 

Konstantopoulos C, Ribaudo H, Ragland K, Bangsberg DR, Li JZ. Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia. Open Forum Infect Dis. 2015;2:ofu119.

Article  PubMed  PubMed Central  Google Scholar 

Castillo-Mancilla JR, Morrow M, Coyle RP, Coleman SS, Zheng J-H, Ellison L, et al. Low-level viremia is associated with cumulative adherence to antiretroviral therapy in persons with HIV. Open Forum Infect Dis. 2021;8:ofab463.

Article  PubMed  PubMed Central  Google Scholar 

Li JZ, Gallien S, Ribaudo H, Heisey A, Bangsberg DR, Kuritzkes DR. Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS. 2014;28:181–6.

Article  CAS  PubMed  Google Scholar 

Leierer G, Grabmeier-Pfistershammer K, Steuer A, Geit M, Sarcletti M, Haas B, et al. Factors associated with low-level viraemia and virological failure: results from the Austrian HIV cohort study. PLoS ONE. 2015;10:e0142923.

Article  PubMed  PubMed Central  Google Scholar 

Maggiolo F, Di Filippo E, Comi L, Callegaro A, Colombo G, Di Matteo S, et al. Reduced adherence to antiretroviral therapy is associated with residual low-level viremia. POR. 2017;8:91–7.

Article  Google Scholar 

Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of Virological rebound in plasma. J Infect Dis. 2012;206:1443–52.

Article  CAS  PubMed  Google Scholar 

Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis. 2007;196:1773–8.

Article  PubMed  Google Scholar 

Goupil De Bouillé J, Collignon M, Capsec J, Guillon L, Le Moal G, Barin F, et al. Low-level HIV viremia is associated with low antiretroviral prescription refill rates and social deprivation. AIDS Care. 2021;33:1445–50.

Article  PubMed  Google Scholar 

Inzaule SC, Bertagnolio S, Kityo CM, Siwale M, Akanmu S, Wellington M, et al. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. AIDS. 2020;34:1559–66.

Article  CAS  PubMed  Google Scholar 

Nanyeenya N, Nakanjako D, Makumbi F, Nakigozi G, Nalugoda F, Kigozi G, et al. Effectiveness of intensive adherence counselling in achieving an undetectable viral load among people on antiretroviral therapy with low-level viraemia in Uganda. HIV Medicine. 2024;25:245–53.

Article  CAS  PubMed  Google Scholar 

Miller LG, Golin CE, Liu H, Hays RD, Hua J, Wenger NS, et al. No evidence of an association between transient HIV viremia (“blips”) and lower adherence to the antiretroviral medication regimen. J Infect Dis. 2004;189:1487–96.

Article  PubMed  Goo